2.810SEK+0.90%Mkt Cap: 375.23M SEKP/E: —Last update: 2026-06-12
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, wh…
Industry Peers
Biotechnology112.95BUSDP/E 26.4
99.40BDKKP/E 19.0
64.11BUSDP/E 14.9
52.33BEURP/E 34.3
48.73BEURP/E 40.1
38.64BUSDP/E 72.5
32.08BSEKP/E 47.5
31.84BUSDP/E 29.1
Indicators:|
Key Statistics
Company
Market Cap375.23M SEK
Enterprise Value320.13M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-76.25M SEK
Revenue/Share—
Last Price2.810 SEK
Fiscal Year EndDec 2019
MR QuarterMar 2026
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.21
PEG—
EV/EBITDA-4.51
EV/Revenue—
P/S—
P/B4.26
EPS (TTM)-0.57
EPS (Forward)-0.12
52W Range
2.53010% of range5.230
52W High5.230 SEK
52W Low2.530 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.66%
ROA-68.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-72.25M SEK
CapEx (TTM)57.00K SEK
FCF Margin—
FCF Yield-16.74%
Net Debt-33.20M SEK
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.01
Current Ratio2.81
Quick Ratio2.70
Book Value/Sh0.6540 SEK
Cash/Share0.2670 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.600 SEK
Target Range3.700 SEK – 8.500 SEK
# Analysts4
Ownership
Shares Out.133.54M
Float117.54M
Insiders15.83%
Institutions20.74%
Technical
SMA 503.010 (-6.7%)
SMA 2003.082 (-8.8%)
Beta0.91
S&P 52W Chg23.71%
Avg Vol (30d)640.90K
Avg Vol (10d)567.68K
Technical Indicators
RSI (14)39.0
MACD-0.0420
MACD Signal-0.0170
MACD Hist.-0.0251
BB Upper3.262 SEK
BB Middle2.984 SEK
BB Lower2.706 SEK
BB Width18.66%
ATR (14)0.1526 SEK
Vol Ratio (20d)1.00x